CDMOs and CROs at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
47 CDMOs and CROs are at ESGCT 2026 — 94 presentations on the program. Most represented: ReiThera (5 on the program), Genezen (4 on the program), Ascend Advanced Therapies (4 on the program). 34 of them have their own page in this guide. As of Oct 16, 2026.
Topic
Top represented
Showing 1–10 of 47 organizations
| Organization | ESGCT 2026 Attendance |
|---|---|
ReiThera Rome, Italy | |
Develops and manufactures genetic vaccines and viral vectors, offering adenoviral, AAV and MVA vector design through clinical-grade production. | Poster Wed Oct 28 1:30pm–3:30pm Recombinant MVA Generation and Purification Using a Duck Cell Line Poster Thu Oct 29 2:00pm–4:00pm A Scalable and Transferable Manufacturing Platform for Multi-Serotype AAV Vector Production Poster Thu Oct 29 2:00pm–4:00pm A novel Gorilla-derived oncolytic Adenovirus with natural lung tropism and selective replication in cancer cells Poster Thu Oct 29 2:00pm–4:00pm AdAAV: A Novel Transfection-Free Platform for High-Titer AAV Manufacturing Poster Thu Oct 29 2:00pm–4:00pm Development of ReiCell-LV, a Suspension HEK293 Platform for Enhanced Lentiviral Vector Production |
Genezen Indianapolis, Indiana | |
Contract development and manufacturing organisation for cell and gene therapies, producing lentiviral and retroviral vectors from plasmid design and cell line development to GMP manufacturing. | Poster Wed Oct 28 1:30pm–3:30pm Addition of sugar to final formulation buffer improves lentiviral and γ-retroviral vector recovery in sterile filtration by potentially stabilizing the viral vector Poster Wed Oct 28 1:30pm–3:30pm One and done: agile Cmc strategies for N-of-1 gene therapies Poster Thu Oct 29 2:00pm–4:00pm A dual optimization strategy: refining IEX elution and eliminating citric acid to improve AAV empty and full capsid separation Poster Thu Oct 29 2:00pm–4:00pm Continuous monitoring of cell and gene therapy processes in stage 3 of Process validation lifecycle Poster Thu Oct 29 2:00pm–4:00pm Development of a no-extraction ddPCR-based method for residual host cell DNA quantitation and sizing in therapeutic viral vectors Poster Thu Oct 29 2:00pm–4:00pm Screening of transfection process parameters related to the complexation reaction between the transfection reagent and plasmid DNS for the impact on rAAV titer in HEK cell host |
Ascend Advanced Therapies Rockville, Maryland | |
Contract development and manufacturing for gene and cell therapies, from early research to commercial supply; combined with ABL since 2024. | Poster Thu Oct 29 2:00pm–4:00pm A cross-sectional analysis of approved AAV gene therapy formulations linking composition, stability, and clinical administration Poster Thu Oct 29 2:00pm–4:00pm A surrogate assay to monitor replication-competent AAV formation using nanopore long-read sequencing Poster Thu Oct 29 2:00pm–4:00pm Enhancing recombinant AAV production in suspension cell culture through targeted cell cycle modulation Poster Thu Oct 29 2:00pm–4:00pm Navigating AAV Manufacturing Complexity: A Comprehensive Comparison of Commercial and Proprietary HEK293 Platforms for Optimized Vector Quality Poster Thu Oct 29 2:00pm–4:00pm Orthogonal purification strategies for AAV: bridging rapid feasibility via ultracentrifugation with scalable chromatography-based manufacturing to support diverse therapeutic timelines. |
Viralgen San Sebastián, Spain | |
AAV contract manufacturer offering process development and GMP vector production, part of Bayer's AskBio. | Poster Wed Oct 28 1:30pm–3:30pm In-line Capacitance Probes Enable Enhanced and Consistent High-Quality rAAV Manufacturing Poster Wed Oct 28 1:30pm–3:30pm Optimization of recombinant Adeno-Associated Virus vector production: Integrating synthetic molecules to enhance vector yield and quality for clinical gene therapy applications Poster Wed Oct 28 1:30pm–3:30pm Repeatability and intermediate precision of a genome integrity assay for rAAV by long-read sequencing Manufacturing, CMC and access Poster Thu Oct 29 2:00pm–4:00pm Investigations of AAV stability under stress conditions using small-scale models |
Lonza Basel, Switzerland | ◆Platinum Sponsor |
Offers cell and gene therapy development and manufacturing services, testing, automation platforms and research tools from discovery to commercial supply. | Poster Wed Oct 28 1:30pm–3:30pm Clinical Translation of Nonviral Gene Editing: Efficient Electroporation of CD34+, NK, and T Cells in large volume Chair Thu Oct 29 1:30pm–2:30pm LUNCHTIME SYMPOSIUM: Lonza Manufacturing, CMC and access Poster Thu Oct 29 2:00pm–4:00pm A robust system for high-titer, platform-agnostic AAV production in HEK293 cell lines Poster Thu Oct 29 2:00pm–4:00pm Examination of reproducibility in 2D MSC culture and 3D extracellular vesicle formation |
AGC Biologics Bothell, Washington | ◆Gold Sponsor |
Global CDMO providing process development, cGMP manufacturing and testing for proteins, plasmid DNA, mRNA, viral vectors and engineered cells. | Poster Thu Oct 29 2:00pm–4:00pm A comparative analysis of integrated and modular platforms for manufacturing T cells genetically modified with lentiviral vectors Poster Thu Oct 29 2:00pm–4:00pm BravoAAVTM: Advancing AAV Vector Manufacturing Through Process and Cell Line Innovation Poster Thu Oct 29 2:00pm–4:00pm From ex vivo to in vivo: leveraging established lentiviral vector manufacturing expertise to meet the next frontier of gene therapy |
◇Silver Sponsor | |
Designs and makes custom vectors, virus packaging, libraries and stable cell lines, plus AAV capsid evolution and GMP plasmid and viral vector manufacturing. | Poster Wed Oct 28 1:30pm–3:30pm An integrated miniaturized plasmid and electroporation workflow for improved non-viral engineering of primary human T cells Poster Wed Oct 28 1:30pm–3:30pm Enhancing AAV targeting for next-generation ocular therapies Poster Thu Oct 29 2:00pm–4:00pm A novel modular split AAV vector system for efficient delivery of large and complex genes |
DINAMIQS Schlieren, Switzerland | |
Contract developer and manufacturer of AAV and lentiviral vectors, with analytics and fill-finish services; part of the Siegfried group. | Poster Wed Oct 28 1:30pm–3:30pm Direct-ligation nanopore sequencing reveals snap-back genome species in rAAV vector preparations Poster Wed Oct 28 1:30pm–3:30pm Multi-Parametric Optimization of Upstream AAV Production for Enhanced Titers and Vector Quality Poster Thu Oct 29 2:00pm–4:00pm Scaling-up rAAV downstream process from 2L process development to 200L for engineering run |
Evotec Hamburg, Germany | |
Drug discovery and development partner offering research, development and manufacturing services to pharma and biotech, including cell therapy work. | Poster Wed Oct 28 1:30pm–3:30pm Immune-shielded iPSC-derived macrophages for off-the-shelf cell therapy of fibrosis Poster Wed Oct 28 1:30pm–3:30pm Off-the-shelf immune-shielded iPSC-derived CAR γδ T cells as novel cell therapy to treat hepatocellular carcinoma Talk Fri Oct 30 12:05pm–1:00pm ATMP development in a changing Europe: An industry perspective on the EU Pharmaceutical Reform Manufacturing, CMC and access |
INITS Mauguio, France | |
Offers CMC, regulatory and quality consulting and runs a shared GMP manufacturing facility where biotechs produce their own clinical batches of biologics and advanced therapies. | Poster Wed Oct 28 1:30pm–3:30pm Comprehensive Risk Assessment Framework for Cell and Gene Therapy Products toward registration: Addressing Nitrosamines, Extractables/Leachables, Elemental Impurities, and Emerging Contaminants for Regulatory Compliance Poster Wed Oct 28 1:30pm–3:30pm The Shared Manufacturing Organization (SMO) model: a multi-technology platform offering flexible and cost-effective alternative for bioproduction Poster Thu Oct 29 2:00pm–4:00pm Strategic Regulatory Designations for Innovative Medicines: An Overview of Existing Pathways in the European Union and the United States, and Opportunities for Cross-Program Compatibility |
Instantly find 20 buyers from CDMOs and CROs
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ESGCT 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction